Pipeline

January 24, 2020

Company	Drug/Device	Medical Condition	Status
LB Pharmaceuticals	LB-102	schizophrenia	phase 1 trial dosing initiated
Stealth BioTherapeutics	SBT-272	mitochondrial dysfunction	phase 1 trial initiated enrolling 60 patients
Rafael Pharmaceuticals	CPI-613® (devimistat) in combination with gemcitabine and cisplatin	advanced, unresectable or metastatic biliary tract cancer	phase 1b/2 trial initiated
BlackThorn Therapeutics	BTRX-335140 (BTRX-140)	major depressive disorder	phase 2 trial initiated
Aldeyra Therapeutics	reproxalap ophthalmic solution	allergic conjunctivitis	phase 3 trial enrolling 120 patients
Wize Pharma	LO2A	dry eye syndrome in patients with Sjögren's syndrome	phase 4 trial enrollment completed with 60 patients
Clovis Oncology	Rubraca (rucaparib)	metastatic castrate-resistant prostate cancer	Priority Review designation granted by the FDA
Fortress Biotech	CUTX-101	Menkes Disease	Rare Pediatric Disease designation granted by the FDA
MedAlliance	Selution SLR drug-eluting balloon	AV-fistula	Breakthrough Device designation granted by the FDA
Ra Medical Systems	DABRA excimer laser system	peripheral vascular stenoses	IDE granted by the FDA
INHIBITOR Therapeutics	SUBA-Itraconazole	metastatic castrate resistant prostate cancer	IND approved by the FDA
Cadent Therapeutics	CAD-1883 Spinocerebellar Ataxia	spinocerebellar ataxia	IND approved by the FDA
AstraZeneca	Imfinzi (durvalumab) and tremelimumab	hepatocellular carcinoma	Orphan Drug status granted by the FDA
Baze	at-home blood test kit	blood nutrient levels	approved by the FDA
Horizon Therapeutics	Tepezza (teprotumumab-trbw)	thyroid eye disease	approved by the FDA
Medtronic	Micra AV pacemaker	atrioventricular block	approved by the FDA
Merck	Keytruda (pembrolizumab) in combination with Inlyta (axitinib)	advanced renal cell carcinoma	approved by Health Canada